Letters to Editor
of events ( 2 ) . It appears that a diff erent approach to reporting of AEs was applied in the plecanatide phase 3 CIC trials. According to the FDA's summary basis of approval for plecanatide, patient reports of diarrhea were recorded only if the events were considered "bothersome":
"Since an increase in the number of BMs from baseline was an expected pharmacodynamic eff ect of plecanatide and would be coded as diarrhea, sites were instructed to only record an AE of diarrhea if the patient reports that it was bothersome [e.g., watery/ mushy stool (Bristol Stool Form Scale [BSFS] score of 6 or 7), with a sense of urgency, etc.] or if the event required treatment or hospitalization. " ( 3 ) Th is description of the methodology used for diarrhea AE collection is not completely clear and raises questions, including:
• If the patient reported diarrhea, but did not specify whether it was bothersome, was the patient further questioned about the event, or was it simply not recorded? • If the sites determined bothersomeness, how was this done? • Did a reportable diarrhea event require specifi c BSFS values and/ or a sense of urgency?
In the spirit of good scientifi c exchange, we ask the authors to provide, in a response letter for American Journal of Gastroenterology , answers to these questions, as well as the specifi c instructions given to sites for determining which diarrhea events were to be recorded as AEs. If diarrhea and diarrhea-like events deemed "non-bothersome" were collected, the overall (i.e., with and without "bothersomeness") diarrhea rates should also be provided. To the Editor: We read with interest the phase 3 trial publication by Miner et al. ( 1 ) for the second FDA-approved GC-C agonist, plecanatide, in American Journal of Gastroenterology . While encouraged that the trial's results appear to further support use of this pharmacologic class in treating patients with chronic idiopathic constipation (CIC), we are concerned that the authors did not disclose non-standard adverse event (AE)reporting methods employed in this trial. Both linaclotide and plecanatide act locally on the luminal surface of the intestinal tract to activate GC-C and are minimally absorbed with negligible systemic exposure. Diarrhea is an expected AE given the pro-secretory characteristics of this pharmacologic class. In linaclotide clinical trials, all spontaneously reported AEs and AEs reported in response to nonleading questions (including diarrhea) were recorded as verbatim terms. Th ereafter, qualifi ers such as bothersome/annoying were used to grade the severity of these AEs, but were not used to rule out recording represents the only large national payer that is committed to authorizing DAA therapy for all patients with chronic HCV without restriction based on the stage of liver fi brosis ( 3 ). With the anticipated approval of two additional oral DAA combination regimens by the US FDA in late 2017 (glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir), increasing price pressure through decreased wholesale acquisition cost (WAC) prices and more signifi cant manufacturer discounts may further encourage broadening of DAA access among US payers. Future research addressing HCV treatment access should focus on ongoing defi cits in access among marginalized populations such as the incarcerated, persons who inject drugs and the homeless, validation and implementation of generic DAA formulations, and application of DAAs in resourcelimited settings outside the United States. Access to curative treatment remains only one of several critical barriers within the broader care cascade (e.g., screening, diagnosis, linkage to care) for which signifi cant improvement is required if we are to achieve the World Health Organization's ambitious objective to eliminate HCV by 2030 ( 4 ). I appreciate the opportunity to have had this research published in the American Journal of Gastroenterology and the opportunity to respond to this "Letter to the Editor". ( 1 ) examines the ever-evolving medical treatment options and strategies for Crohn's disease (CD) in this cohort and concludes that there has been an improvement in long-term outcomes over the past 20 years as evidenced by decreased hospitalizations and surgery rates. Th e authors astutely mention that the aforementioned improvements were not signifi cantly related to the use of biologics et al. Th e statement refl ects recognition by the FDA that for a patient in a clinical trial of constipation, an increase in the number of BMs over baseline could represent either an expected and desired eff ect of the medication or if taken too far could represent an AE of diarrhea. As an investigator in this trial, I interpret "an increased number of stools" to be a carefully worded phrase regarding the need to consider a patient's verbatim report of "an increased number of stools" as a potential therapeutic eff ect that should be distinguished from an AE. Th e FDA statement continues to provide guidance that to distinguish between a desired therapeutic eff ect and an adverse event, the increase in the number of bowel movements should be associated with unexpected or unwanted symptoms (i.e., "bothersome"), require treatment or result in hospitalization. Furthermore, the guidance is specifi c to the verbatim concept of "increase in the number of BMs" and it does not pertain to a verbatim report of "diarrhea, " which would be recorded as such.
CONFLICT OF INTEREST
In answer to the specifi c questions raised in the letter:
1 . If the patient reported diarrhea, but did not specify whether it was bothersome, was the patient further questioned about the event, or was in simply not recorded? If the patient indicated that they had experienced "diarrhea" the event was recorded in the case report form (CRF) as is standard in clinical trials. As with all potential AEs, the clinical investigator must investigate the complaint to determine the nature of the AE, the severity of the AE and the relationship to the study drug; no determination of bothersomeness was conducted. To the Editor: I am pleased to have the opportunity to respond to the letter to the editor ( 1 ) regarding the recent publication investigating the eff ect of plecanatide in patients with chronic idiopathic constipation (CIC) ( 2 ) . Th e letter asks for clarification regarding the adverse event (AE) collection process for diarrhea. In plecanatide trials, all spontaneously reported AEs, as well as AEs reported in response to nonleading questions were recorded as verbatim terms, including the verbatim term of diarrhea. Th e FDA statement referenced in the letter may have been misinterpreted by Currie
